Back to search

Article

Utilizing novel fluorothymidine PET imaging in a phase I study of veliparib on an intermittent and continuous schedule given in combination with carboplatin in metastatic breast cancer

2020-01-24

Abstract excerpt

<h4>ABSTRACT</h4> Poly(ADP-ribose) polymerase inhibitors are FDA-approved for treatment of BRCA mutated metastatic breast cancer (MBC). Prior studies demonstrated benefit of adding oral PARPi veliparib to carboplatin and paclitaxel in BRCA mutation positive patients with MBC. We sought to find the recommended phase II dose (RP2D) and schedule of veliparib in combination with carboplatin in patients with advanced b...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d4f8a8b3-97ae-54f5-ac27-fc2a7168aca0
DOI
10.1101/2020.01.20.20018218
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Utilizing novel fluorothymidine PET imaging in a phase I study of veliparib on an intermittent and continuous schedule given in combination with carboplatin in metastatic breast cancerDOI 10.1101/2020.01.20.20018218
Phase II Trial of Veliparib and Temozolomide in Metastatic Breast Cancer Patients With and Without BRCA1/2mutationsSemantic proximity
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.Semantic proximity
An Open Label, Pilot Study of Veliparib and Lapatinib in Patients with Metastatic, Triple Negative Breast CancerSemantic proximity
A PET imaging agent for evaluating PARP-1 expression in ovarian cancerSemantic proximity
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination RepairSemantic proximity
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaSemantic proximity
Profile of veliparib and its potential in the treatment of solid tumorsSemantic proximity
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 studySemantic proximity
Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.Semantic proximity
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.Semantic proximity
Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).Semantic proximity
A novel <sup>18</sup> F-labeled brain penetrant PET ligand for imaging poly(ADP-ribose) polymerase-1Semantic proximity
Select a neighboring publication to make it the new centre.